SCHEMBL745345

SCHEMBL745345

CC(C)C(C)OC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14627140 1.00
SCHEMBL29728550 0.90 LMNA (0.48)
Pentabamate SCHEMBL636717 0.85 LMNA (0.44)
SCHEMBL29728537 0.84 LMNA (0.40)
Methacrylic Acid SCHEMBL21483482 0.83 TDP1 (0.40)
SCHEMBL18043494 0.82
SCHEMBL28623543 0.82
SCHEMBL8755732 0.82
SCHEMBL28623541 0.82
SCHEMBL14592888 0.82 LMNA (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112552207-A Production method of anisyl nitrile 郑州科旷生物科技有限公司 2021-03-26 CN claimed
EP-1906945-B1 HCV INHIBITORS VIROBAY INC (US) 2015-08-05 EP claimed
EP-2431379-A2 HCV inhibitors Virobay, Inc. (US) 2012-03-21 EP claimed
US-20100266537-A1 HCV INHIBITORS VIROBAY, INC. (US) 2010-10-21 US claimed
US-7608592-B2 HCV inhibitors VIROBAY, INC. (US) 2009-10-27 US claimed
EP-1906945-A4 HCV INHIBITORS VIROBAY INC (US) 2009-07-15 EP claimed
WO-2008086053-A1 HCV INHIBITORS VIROBAY, INC. (US) 2008-07-17 WO claimed
US-20080161254-A1 HCV INHIBITORS VIROBAY, INC. (US) 2008-07-03 US claimed
EP-1906945-A2 HCV INHIBITORS Virobay, Inc. (US) 2008-04-09 EP claimed
US-20070054864-A1 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections QUEST DIAGNOSTICS INVESTMENTS LLC 2007-03-08 US claimed
WO-2007005838-A2 HCV INHIBITORS VIROBAY, INC. (US) 2007-01-11 WO claimed
WO-2024096066-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE 第一工業製薬株式会社 2024-05-10 WO disclosed
WO-2024094637-A1 PROCESS FOR THE PREPARATION OF CYCLIC KETONES ARXADA AG (CH) 2024-05-10 WO disclosed
WO-2024096067-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN 第一工業製薬株式会社 2024-05-10 WO disclosed
EP-4361148-A1 HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE Albius Sciences Alpha Private Limited (SG) 2024-05-01 EP disclosed
EP-0122202-B1 TETRA-ALKYL-2,2,5,5-CYCLOHEXANON-4-OL-1 AND ITS SULFONATED DERIVATIVES, PROCESS AND INTERMEDIATES FOR ITS PREPARATION AND ITS USE IN THE SYNTHESIS OF CIS-CYCLOPROPANLACTONES ROUSSEL-UCLAF (FR) 1987-06-16 EP disclosed
US-4610826-A INTERMEDIATES FOR FUNGICIDES ROUSSEL UCLAF (FR) 1986-09-09 US disclosed
WO-1984004090-A1 NEW TETRA-ALKYL-2, 2, 5, 5-CYCLOHEXANONE-4 ol-1 AND SULPHONYLATED DERIVATIVES THEREOF, PREPARATION INTERMEDIARIES AND PROCESS AND THEIR APPLICATION TO THE SYNTHESIS OF CYCLOPROPANIC CIS LACTONES ROUSSEL UCLAF (FR) 1984-10-25 WO disclosed
EP-0122202-A2 Tetra-alkyl-2,2,5,5-cyclohexanon-4-ol-1 and its sulfonated derivatives, process and intermediates for its preparation and its use in the synthesis of cis-cyclopropanlactones ROUSSEL-UCLAF (FR) 1984-10-17 EP disclosed
US-4207235-A Selective epoxidation of steroidal bromohydrins SYNTEX (U.S.A.) INC. (US) 1980-06-10 US disclosed